Kelleher Financial Advisors Purchases 2,678 Shares of Stryker Corporation $SYK

Kelleher Financial Advisors raised its position in shares of Stryker Corporation (NYSE:SYK) by 208.9% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,960 shares of the medical technology company’s stock after acquiring an additional 2,678 shares during the period. Kelleher Financial Advisors’ holdings in Stryker were worth $1,247,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. VanderPol Investments L.L.C. grew its position in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after acquiring an additional 28 shares during the last quarter. KCM Investment Advisors LLC increased its holdings in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares in the last quarter. Rossby Financial LCC raised its position in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the last quarter. Tcfg Wealth Management LLC raised its position in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the last quarter. Finally, West Michigan Advisors LLC boosted its stake in Stryker by 0.4% in the fourth quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company’s stock worth $2,631,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.1%

Shares of NYSE SYK opened at $338.80 on Monday. The company’s 50 day simple moving average is $324.61 and its 200 day simple moving average is $333.40. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The firm has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analysts Set New Price Targets

Several brokerages have recently commented on SYK. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. Royal Bank Of Canada reduced their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Citizens Jmp decreased their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.